Cardiology CME | Cardiology

CME Managing Today's EP Challenges with NOAC Use

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.

This engaging activity featuring a superb faculty provides electrophysiologists and others with the best information available on managing stroke prevention around the

This activity is supported by an educational grant from Synageva BioPharma Corp.

Hereditary dyslipidemias are caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and LDL

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and associated complications. Despite evidence linking

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with idiopathic pulmonary fibrosis.

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome (ACS), a condition that can result in substantial

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with acute coronary syndrome.

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, over 780,000 persons annually will experience an acute coronary syndrome (ACS), a condition that can result in substantial

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome (ACS), a condition that can result in substantial

The ACS Portal is a center for the latest information on ACS. Learn from leading experts as they provide perspective on the screening, treatment, management and

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome (ACS), a condition that can result in substantial

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

Acute coronary syndrome (ACS) can result in substantial morbidity or death. To reduce the risk of cardiovascular death, stroke, or non-fatal myocardial infarction in

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

Managing patients with acute coronary syndrome (ACS), as well as choosing the most appropriate antiplatelet therapy and determining its duration, can represent a

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with statin intolerance.

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

Acute coronary syndrome (ACS) can result in substantial morbidity or death. To reduce the risk of cardiovascular death, stroke, or non-fatal myocardial infarction in

This activity is supported by an educational grant from Genentech, Inc.

The Centers for Disease Control and Prevention report an annual 130,000 stroke-related fatalities in the United States alone. Stroke is the cause of 1 in every 19 deaths

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome (ACS), a condition that can result in substantial

Those with acute coronary syndrome who undergo percutaneous coronary intervention (PCI) to open a blocked coronary artery are prescribed an oral antiplatelet (OAP)

This CME activity will focus on the diagnosis and management of patients with familial hypercholesterolemia.

This activity is supported by an educational grant from Amgen, Inc.

Appropriate therapies for various dyslipidemias remain a challenge for practitioners struggling to reduce residual risk for cardiovascular disease, even after statin

Heart disease is the leading cause of death in the United States for men and women, claiming approximately 1 million lives each year.This statistic alone

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for atherosclerotic disease, pancreatitis, and associated complications. With new therapies

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

This activity is supported by an educational grant from Eisai, Inc. and Vivus, Inc.

Obesity is associated with a wide range of comorbid conditions, including diabetes, hypertension, sleep apnea, and cardiovascular disease. Clinicians must consider the

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options include behavior modification, commercially

This activity is supported by an educational grant from Vivus, Inc.

Obesity is suboptimally managed in clinical practice despite the availability of relevant guidelines and evidence-based interventions. Many physicians remain uncertain

This activity is supported by educational grants from Lilly USA, LLC and Novo Nordisk.

The prevalence of type 2 diabetes mellitus has escalated in recent years and targeting treatment continues to be a difficult goal. Clinicians will have to become

This activity is supported by an educational grant from EMD-Serono.

Clinicians who manage patients with HIV must be aware of how to screen for, diagnose, and treat metabolic abnormalities and body shape changes. This monograph will

This activity is supported by an educational grant from Genentech.

Elevated plasma triglycerides are linked to insulin resistance, and both disorders are associated with increased cardiovascular risk. Experts often debate which

Read more from the original source:
Cardiology CME | Cardiology